TITLE

Antiviral Briefs

PUB. DATE
August 2001
SOURCE
AIDS Patient Care & STDs;Aug2001, Vol. 15 Issue 8, p443
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Presents updates on antiviral drugs compiled as of August 2001. Effect of two active ingredients in milk thistle on liver enzymes; Effects of protease inhibitors on weight and other growth parameters in children and adolescents with HIV infection; Use of genotypic resistance testing in the selection of antiretroviral agents.
ACCESSION #
5523170

 

Related Articles

  • Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy. Anis, A.H.; Hogg, R.S.; Wang, X-h.; Yip, B.; Palepu, A.; Montaner, J.S.G.; O’Shaughnessy, M.V.; Schechter, M.T.; Montaner, J S; O'Shaughnessy, M V // PharmacoEconomics;1998, Vol. 13 Issue 6, p697 

    The purpose of this study is to model the potential economic impact of viral load-driven triple drug combination (including a protease inhibitor) antiretroviral therapy on incremental drug and hospitalisation costs among individuals with HIV disease. Individuals included in the study were...

  • Combination Treatment for HIV.  // Combination Treatment for HIV;4/1/2004, p1 

    The article presents information about combination treatment for human immunodeficiency viruses (HIV). It enumerates the four main types of HIV drugs namely nucleoside analogues, non-nucleoside analogues, protease inhibitors and fusion inhibitors. It cites the side effects of combining these...

  • Antiviral Briefs.  // AIDS Patient Care & STDs;Oct2000, Vol. 14 Issue 10, p567 

    Presents various medical news briefs related to side effects of antiviral drugs for HIV infections. Ability of protease inhibitors to cause sexual dysfunction; Role of highly active antiretroviral therapy in causing curly hair; Interaction between Viagra and ritonavir or saquinavir.

  • EFAVIRENZ POTENT IN ADULTS.  // AIDS Patient Care & STDs;Mar2000, Vol. 14 Issue 3, p170 

    Cites the findings of a DuPont 006 study regarding the use of efavirenz when compared to the protease inhibitor indinavir. Support for the use of efavirenz among HIV patients who are treatment-naive; Random assignments into possible treatment regimens.

  • MEXVIR 2: Eficacia de esquemas antirretrovirales con nelfinavir más dos inhibidores de transcriptasa reversa nucleósidos en pacientes mexicanos con ifección por VIH.  // Medicina Interna de Mexico;mar/abr2007, Vol. 23 Issue 2, p113 

    Background: Since 2003, recommendations of antiretroviral treatment privilege the prescription of protease inhibitors reinforced with ritonavir. In Mexico they are being indicated without pharmacological reinforcement. This paper reviews national experience related to the efficacy and safety of...

  • Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates. Knops, Elena; Däumer, Martin; Awerkiew, Sabine; Kartashev, Vladimir; Schülter, Eugen; Kutsev, Sergey; Brakier-Gingras, Léa; Kaiser, Rolf; Pfister, Herbert; Verheyen, Jens // Journal of Antimicrobial Chemotherapy (JAC);Jul2010, Vol. 65 Issue 7, p1472 

    Objectives: To analyse HIV Gag cleavage site (CS) and non-CS mutations in HIV non-B isolates from patients failing antiretroviral therapy.

  • The prevalence of resistance-associated mutations to protease and reverse transcriptase inhibitors in treatment-naïve (HIV1)-infected individuals in Casablanca, Morocco. Bakhouch, Khadija; Oulad-Lahcen, Ahd; Bensghir, Rajae; Blaghen, Mohamed; Elfilali, Kamal Marhoum; Ezzikouri, Sayeh; Abidi, Omar; Hassar, Mohamed; Wakrim, Lahcen // Journal of Infection in Developing Countries;2009, Vol. 3 Issue 5, p380 

    Background: The widespread use of antiretroviral agents and the growing occurrence of HIV-1 strains resistant to these drugs have given rise to serious concerns regarding the transmission of resistant viruses to newly infected persons, which may reduce the efficacy of a first-line antiretroviral...

  • Apparent Resolution of Type 2 Diabetes Mellitus after Initiation of Potent Antiretroviral Therapy in a Man from Africa with HIV Infection. Koeppe, John; Kosmiski, Lisa // Clinical Infectious Diseases;5/15/2006, Vol. 42 Issue 10, pe79 

    We describe a 52-year-old African man with human immunodeficiency virus infection and type 2 diabetes mellitus whose diabetes resolved as viral replication was suppressed with protease inhibitor-based antiretroviral therapy. This case suggests that human immunodeficiency virus infection itself...

  • Proteochemometric modeling of HIV protease susceptibility. Lapins, Maris; Eklund, Martin; Spjuth, Ola; Prusis, Peteris; Wikberg, Jarl E. S. // BMC Bioinformatics;2008, Vol. 9, Special section p1 

    Background: A major obstacle in treatment of HIV is the ability of the virus to mutate rapidly into drug-resistant variants. A method for predicting the susceptibility of mutated HIV strains to antiviral agents would provide substantial clinical benefit as well as facilitate the development of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics